Can't wait until 2019

Discussion in 'Amgen' started by Generic Velcade, Sep 27, 2016 at 2:40 PM.

Tags: Add Tags
  1. Thanks for failing to be better. Generic Velcade = cost effective!

    #DontcombinewithKyprolis
    #save your $$$ for Darzelex and Revlimid

    #Peak sales for kyprolis down

    #onyx not worth the price

    #kyprolis no longer MM foundational drug for combos

    #layoffs once repatha outcomes disappoint

    #amgen desperate for growth

    #banker bob to sell you losers
     

  2. anonymous

    anonymous Guest

    Takeda Pharmaceutical Co. lost a court ruling that could shave years off the time before generic-drug versions of its top-selling cancer drug Velcade hits the market.

    A patent on the medicine that expires in 2022 is invalid, U.S. District Judge Gregory Sleet concluded Thursday. He agreed with generic-drug makers who said the patent for a formulation of the drug is “the inherent result of an obvious process.”

    The ruling means that a generic version of the medicine could enter the market when another patent expires in May 2017.


     
  3. anonymous

    anonymous Guest

    So velcade generics by May? Wow, this is going to affect Kyprolis real soon as it will be the preferred PI in triplet combos with Darzelex or Revlimid.

    Two brand over agents is Over 250k, a third would make it >350k a patient. The odd man out if they need PI is Kyprolis when Velcade could be had for much less.
     
  4. anonymous

    anonymous Guest


    CIA in 2018